Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments
Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments
Eli Lilly is building a case against businesses that are selling knockoffs of the company's Zepbound and Monjaro. Compounding pharmacies have been capitalizing on Lilly seeing supply constraints and shortages while demand remains high.Eli Lilly And Co (NYSE:LLY) is one of several companies benefitting from demand for weight loss drugs. The company is also seeing competition in the market including knockoff drugs that it said could be unsafe.
禮來（紐交所:LLY）是受惠於減肥藥需求的幾家公司之一。該公司在市場上也面臨競爭，包括可能不安全的仿冒藥。
What Happened: A recent report says Eli Lilly is seeking medical records of people who took knockoff weight loss drugs.
事件經過：最近一份報告稱，禮來正在尋找使用仿冒減肥藥的人的醫療記錄。
The request, reported by Bloomberg, is being done for safety reasons according to the pharmaceutical company.
據彭博報道，這一請求是出於藥品公司的安全考慮。
Eli Lilly is building a case against businesses that are selling knockoffs of the company's Zepbound and Monjaro. Compounding pharmacies have been capitalizing on Lilly seeing supply constraints and shortages while demand remains high.
禮來正在針對那些出售公司的Zepbound和Monjaro仿冒品的企業提出訴訟。在供應不足和需求持續高漲的情況下，調劑藥房一直在利用禮來的形勢。
Lilly has said that the quality of the compounding pharmacies products are inferior and questions the safety profile of the treatment.
禮來表示，調配藥房產品的質量較差，並質疑該治療方案的安全性。
A letter viewed by Bloomberg requested information from a patient who took a Lilly product from a compounded pharmacy.
彭博查看的一封信件要求一位服用調配藥房禮來產品的患者提供信息。
"We would appreciate if you could complete the enclosed form and sign the Authorization for Release of Medical Information so that we can obtain more details from the treating physician around your experience," the letter says.
「我們將不勝感激，如果您能填寫隨信附上的表格，並簽署釋放醫療信息的授權，以便我們可以從治療醫生那裏獲取更多關於您經歷的詳細信息，」信中稱。
Along with items like the letter, Eli Lilly also took out an advertisement in national publications encouraging patients to make sure they are taking the "real product."
除了這樣的信件之外，禮來還在國家出版物上刊登了廣告，鼓勵患者確保他們正在服用的是「真正的產品」。
Read Also: Can Novo Nordisk's Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes
另請閱讀：能夠諾和諾德的減肥藥奧塞普對阻止毀滅性成癮危機有幫助嗎？新研究顯示可以
Why It's Important: Obtaining medical records could be a key in Eli Lilly's battle against compounding pharmacies. The short supply of Lilly and other companies' weight loss drugs helped the argument for a legal loophole that allows compounding of drugs when a supply constraint happens.
爲什麼很重要：獲取醫療記錄對於禮來抗擊混合藥房可能是關鍵。禮來和其他公司減肥藥物的短缺有助於引發一項法律漏洞的論點，該漏洞允許在供應短缺時混合藥物。
If Eli Lilly can prove that the drugs are not as safe and are causing side effects or harm to patients, it could help put a stop to compounding pharmacies. Without proof, Eli Lilly may fall victim to the legal loophole and the issue of soaring demand for its own products.
如果禮來能夠證明這些藥物並不安全，會導致患者出現副作用或傷害，這可能有助於制止混合藥房。沒有證據的話，禮來可能會成爲法律漏洞和對自家產品需求激增問題的犧牲品。
Eli Lilly reported second-quarter revenue of $11.3 billion, up 36% year-over-year. Mounjaro and Zepbound had revenue of $3.1 billion and $1.2 billion, respectively, seeing significant gains in the quarter.
禮來報告第二季度營業收入爲113億美元，同比增長36%。蒙加洛和澤普邦德分別實現31億美元和12億美元的營收，在季度中取得顯著增長。
The pharmaceutical company increased its full-year guidance as a result of the second-quarter results and increasing demand for several products.
由於第二季度業績和對多種產品需求增加的結果，這家藥品公司增加了全年指引。
LLY Price Action: Eli Lilly stock closed Wednesday at $924.56 versus a 52-week trading range of $516.57 to $972.53. Eli Lilly stock is up 56% year-to-date in 2024.
LLY 價格走勢：禮來股票週三收盤價爲924.56美元，相比52周交易區間的516.57美元至972.53美元，禮來股票在2024年至今上漲了56%。
- Eli Lilly's Early Alzheimer's Treatment Donanemab Scores Japanese Approval, Its Second Largest Market
- 禮來早期阿爾茨海默病治療藥多那諾單抗獲得日本批准，這是它的第二大市場。
Photo: Shutterstock
Photo: shutterstock
譯文內容由第三人軟體翻譯。